About me
Miriam Jacobs, MD, is board-certified and fellowship-trained in medical oncology at MedStar Georgetown Cancer Institute at MedStar Georgetown University Hospital. As a specialist in early and advanced breast cancers, Dr. Jacobs provides chemotherapy, hormone therapy, immunotherapy, precision medicine, and clinical trials. She is also a member of the American Association of Cancer Research, the American Society of Hematology, and the American Society of Clinical Oncology.
Dr. Jacobs’ approach to care focuses on providing individualized and holistic treatments. She begins by talking with patients to learn about their medical histories and health goals. She then collaborates with an experienced team of radiation oncologists and surgeons to develop comprehensive and tailored wellness plans. She also educates patients about natural, traditional, and state-of-the-art cancer treatments.
Dr. Jacobs is dedicated to advancing the field of precision medicine – an innovative form of care that uses people’s own cells to develop highly personalized prevention, diagnosis, and treatment options. She is particularly interested in providing hormone receptor-positive, CAR T-cell, and CAR NK-cell therapies to improve the health of breast cancer survivors. Referring physicians should know that she is available to give second opinions and discuss clinical trial opportunities.
Philosophy of care
“Research creates endless possibilities to discover new methods of treating complex diseases or enhancing people’s lives. As a clinical researcher, I’m passionate about contributing to the collection of knowledge that can lead to immediate medical solutions or future health innovations. I’m also grateful to clinical trial participants who are true healthcare pioneers and heroes.”
About the MedStar Georgetown Cancer Institute
MedStar Georgetown is part of the MedStar Georgetown Cancer Institute, which combines medical expertise, the latest therapies, and research across MedStar Health. Our research engine, the Georgetown Lombardi Comprehensive Cancer Center, is the only National Cancer Institute-designated comprehensive cancer center in the Washington, D.C., region. This partnership means we provide access to cutting-edge clinical trials and the latest breakthroughs in cancer care.
Clinical areas of focus
- Breast Cancer Surgery
- Breast Cancer Treatment
- Mammaprint Testing
- Radioembolization Of Breast Cancer
Procedures I perform
- Ambulatory Phlebectomy
- Antiangiogenic Therapy
- Blood Draws
- Blood Transfusion
- Bone Density Scan
- Breast Cancer
- Breast Cancer Surgery
- Breast Cancer Treatment
- Breast Reconstruction
- Cancer Awareness
- Cancer Rehabilitation
- Cancer Risk Assessment
- Cancer Support
- Cancer Survivorship
- Chemotherapy Administration
- Cholecystectomy
- Clinical Trials For Breast Cancer Treatment
- Diagnostic Breast Imaging
- Disease Prevention
- Factor Vii Infusion
- Genetic Counseling
- Hematology Consultation
- Hepatic Artery Infusion
- Hormone Replacement Therapy
- Hospice Care Consultation
- Immunotherapy
- Intravenous (IV) Fluids
- Introduction Of Antineoplastic
- Mammaprint Testing
- Mep (MOTOR EVOKED POTENTIALS)
- Mesenchymal Stem Cell Transplant
- Oncology Consultation
- Orthopedic Urgent Care
- Pain Management Consultation
- Palliative Care Consultation
- Palliative Care Coordination
- Pathology Consultation
- Patient Navigation
- Peer Support Groups
- Peripheral Blood Stem Cell Transplantation
- Platelet Transfusion
- Radioembolization Of Breast Cancer
- Red Blood Cell Transfusion
- Removal Of Central Venous Access Device
- Removal Of Central Venous Catheter
- Single Photon Emission Computed Tomography
- Supportive Care
- Symptom Management Consultation
- Tumor Immunohistochemistry
- Tumor Marker Testing
- Wellness Services
Practice locations
Distance from Change Location Enter your Location
3800 Reservoir Rd NW
Lombardi Cancer Center
Washington, DC, 20007
Insurance
This list represents the major payors accepted by MedStar Health. NOTE: Payor contracts change and not all plans associated with a payor may be covered. Payors may offer multiple plans. If you have a question related to your insurance, please contact your insurance plan directly. Contact information is located on your health insurance ID card. *Denotes limited participation. Specific providers and practices may NOT be participating. Please contact your insurance plan directly.
-
List of insurance plans we accept
- Aetna
- CareFirst BlueCross BlueShield of Maryland
- Cigna Health Care
- Kaiser Permanente*
- MedStar Select (Administered by CareFirst)
- United HealthCare
- Aetna
- CareFirst BlueCross BlueShield of Maryland
- Healthspring
- Humana
- Medicare & Railroad Medicare
- United HealthCare
- Aetna Better Health of Maryland *
- Medical Assistance/Medicaid
- MedStar Family Choice MD
- Priority Partners *
- United HealthCare Community Health Plan MD
- Wellpoint MD
- AmeriHealth Caritas
- Health Services For Children With Special Needs (HSCSN)
- Medical Assistance/Medicaid
- MedStar Family Choice DC
- Johns Hopkins Employer Health Programs *
- Johns Hopkins US Family Health Plan *
- MultiPlan
- Private Healthcare Systems
- Tricare/Humana Military
- VA Community Care Network (VACCN)
Videos
Education
Board Certification: American Board of Internal Medicine, Internal Medicine
Board Certification: American Board of Internal Medicine, Medical Oncology
Fellowship: Washington University School of Medicine (2021)
Residency: University of California San Diego (2015)
Medical School: Medical School for International Health at Ben Gurion University (2012)
Awards
- Abstract Achievement Award, American Society of Hematology (December 2019) Dean’s Scholar Award, Washington University School of Medicine (July 2022-Present)
Hospital affiliations
News and publications
A Noncompetitive Inhibitor of Serotonin Transport, Acts by Stabilizing the Cytoplasmic-Facing Form of the Transporter, Journal of Biological Chemistry, August 2007
A Conformational Mechanism for Neurotransmitter Transporters, Proceedings of the National Academy of Sciences, July 2008
A Conserved Asparagine Residue in TM1 of the Serotonin Transporter Dictates Chloride-Coupled Neurotransmitter Transport, Journal of Biological Chemistry, July 2011
Use of Low Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small Cell Lung Cancer, JCO Precision Oncology, 2018
Genomic Landscape of Appendiceal Neoplasms, JCO Precision Oncology, 2018
The Use of Ruxolitinib for Acute Graft-Versus Host Disease Developing After Solid Organ Transplantation, American Journal of Transplantation, February 2020
Outcomes of Patients with Large B-Cell Lymphoma Progressing After Axicabtagene Cilolecuel Therapy, Blood, April 1, 2021
Memory-Like Differentiation Enhances NK Cell Response to Melanoma, Clinical Cancer Research, August 3, 2021
CD7 Deleted Hematopoietic Stem Cells Can Restore Immunity After CAR T-Cell Therapy, Journal of Clinical Investigation Insights, August 23, 2021
Systemic IL-15 Promotes Allogeneic Cell Rejection in Patients Treated with Natural Killer Cell Adoptive Therapy, Blood, February 24, 2022
Hematopoietic Cell Transplantation Donor-Derived Memory-Like NK Cells Functionally Persist After Transfer Into Patients with Leukemia, Science Translational Medicine, February 23, 2022
Severity of Cytokine Release Syndrome Influences Outcomes After Axicabtagene Ciloleucel for Large B Cell Lymphoma, Clinical Lymphoma Myeloma and Leukemia, October 22, 2022
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice, Journal of Clinical Oncology, December 2022